Objective: To describe the efficacy, safety and tolerability of lurasidone for the acute treatment of schizophrenia using the metrics number needed to treat (NNT) and number needed to harm (NNH). Methods: Study data were pooled from six Phase II and III, 6-week, randomized, placebo-controlled trials that were conducted to test the efficacy and safety of lurasidone for the acute treatment of schizophrenia. Included were the following interventions: fixed doses of lurasidone 20, 40, 80, 120 and 160 mg/d; haloperidol 10 mg/d; olanzapine 15 mg/d; quetiapine extended-release 600 mg/d; placebo. The following outcomes were assessed: responder rates as defined by a reduction of ≥20, 30, 40 or 50% from baseline on the Positive and Negative Syndrome Scale (PANSS) total score; study completion; discontinuation due to an adverse event (AE); weight gain ≥7% from baseline; incidence of spontaneously reported AEs; incidence of total cholesterol ≥240 mg/dL, low-density lipoprotein cholesterol ≥160 mg/dL, fasting triglycerides ≥200 mg/dL and glucose ≥126 mg/dL at endpoint. NNT for the efficacy outcomes were calculated after excluding one failed study. NNH for the safety/tolerability outcomes were calculated using all six studies. Likelihood of being helped or harmed (LHH) was also calculated to illustrate trade-offs between outcomes of improvement ≥30% on the PANSS vs. incidence of akathisia, nausea, sedation, somnolence and parkinsonism. Results: NNT vs. placebo for PANSS reductions ≥30% were 6, 6, 7 and 4 for lurasidone doses of 40, 80, 120 and 160 mg/d, respectively, and 4 and 3 for olanzapine 15 mg/d and quetiapine extended-release 600 mg/d, respectively. Lurasidone was not associated with any statistically significant disadvantages over placebo for weight gain or metabolic abnormalities; NNH vs. placebo for weight gain ≥7% from baseline was 4 for olanzapine and 9 for quetiapine extended-release in contrast to a NNH for this outcome ranging from 43 to 150 for lurasidone 40-160 mg/d. The 5 most consistently encountered adverse events attributable to lurasidone were akathisia, nausea, sedation, somnolence and parkinsonism, with NNH vs. placebo for lurasidone 40-120 mg/d ranging from 6 (akathisia with 120 mg/d) to 30 (parkinsonism with 80 mg/d). Lurasidone 160 mg/d appeared better tolerated than doses of 40, 80 or 120 mg/d for akathisia, nausea, sedation or somnolence, with no NNH values for these adverse events for 160 mg/d vs. placebo being statistically significant. LHH was favorable for lurasidone when contrasting PANSS reductions vs. adverse events. Conclusions: NNT and NNH can help quantify efficacy, safety and tolerability outcomes and place lurasidone into clinical perspective. Advantages for lurasidone include a low propensity for weight gain and metabolic abnormalities. More commonly encountered adverse events include akathisia, nausea, sedation, somnolence and parkinsonism, but NNH values are generally in the double digits, reflecting an overall tolerable profile. Individual patient characteristics, values and preferences will need to be considered when selecting lurasidone over other antipsychotics. MD, MPH, 11 Medical Park Drive, Suite 106, Pomona, NY 10970 Phone: 845-362-2081; Fax: 845-362-8745; E-mail: nntman@gmail.com Submitted: October 17, 2011; Revised: January 3, 2012; Accepted: February 9, 2012 Leslie Citrome 
Clinical Implications
Lurasidone is FDA-approved for the treatment of schizophrenia based on a subset of the clinical trial data now available. NNT and NNH can help quantify efficacy, safety and tolerability outcomes and place lurasidone into clinical perspective. Advantages for lurasidone include a low propensity for weight gain and metabolic abnormalities. The five most consistently encountered adverse events attributable to lurasidone are akathisia, nausea, sedation, somnolence and parkinsonism, but NNH values are generally in the double digits, reflecting an overall tolerable profile. Individual patient characteristics, values and preferences will need to be considered when selecting lurasidone over other antipsychotics.
binding affinity (antagonist) for the serotonin 5-HT7 receptor. Lurasidone has moderate affinity for serotonin 5-HT1A (partial agonist) and noradrenaline α2c (antagonist) receptors. Lurasidone has little to no appreciable affinity for histamine H1 and acetylcholine M1 receptors.
The efficacy and short-term tolerability of lurasidone for the treatment of acute schizophrenia has been tested in several 6-week, randomized, placebo-controlled trials at fixed doses ranging from 20 to 160 mg, administered once daily (2-6). As per the U.S. product label (1), and based on the data available at the time of approval, the recommended starting dose is 40 mg administered once daily. The maximum recommended dose is 80 mg/d. When examining data from the 4 positive trials available at the time of FDA approval, fixed doses of 120 mg/d did not produce greater improvement than seen at lower doses, but were associated with a higher propensity for somnolence and akathisia. As per the product label, lurasidone is associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, prolactin, or the electrocardiogram QT interval.
Number needed to treat (NNT) and number needed to harm (NNH) are measures of effect size and indicate how many patients would need to be treated with one agent instead of the comparator in order to encounter one additional outcome of interest (7, 8) . NNT is traditionally used to denote potential desirable outcomes (benefits) that a clinician and patient would want to encounter and NNH is ordinarily used to denote potential undesirable outcomes (harms) that a clinician and patient would like to avoid. Both NNT and NNH are calculated using the same formula. Some advocate for using the terms number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNTH), instead of NNT and NNH, respectively (8) . Both sets of terms are commonly found in the medical literature. Nevertheless, NNT and NNH offer the clinician a means of quantifying clinical relevance or "clinical significance. " Lower NNTs (or NNHs) are evidenced when there are large differences between the interventions in question. For example, a NNT of 2 would be a very large effect size, as a difference is encountered after treating 2 patients with one of the interventions versus the other. A NNT of 50 would mean little difference between the two interventions, as it would take treating 50 patients to encounter a difference in outcome. A useful medication is one with a low NNT and a high NNH when comparing it with another intervention; a low NNT and a high NNH would mean one is more likely to encounter a benefit than a harm. A rule of thumb is that a single digit NNT vs. placebo for an efficacy measure suggests that the intervention has potentially useful advantages, and that double digit or higher NNHs vs. placebo for adverse outcomes indicate that the intervention is potentially tolerable.
Likelihood of being helped or harmed (LHH) can be a useful way of synthesizing data regarding benefits and risks (10-12). LHH is calculated using the following formula: LHH=(1/NNT)/(1/NNH)=NNH/NNT. In general, a LHH greater than 1 would mean the likelihood to be helped is greater than the likelihood to be harmed. For a LHH less than 1, the reverse is true. Choosing which NNH and NNT to use in calculating LHH requires careful consideration so that the outcomes being assessed are well matched and consistent with a patient's values and preferences (11, 12) .
The aim of this report is to apply NNT, NNH and LHH in order to appraise the lurasidone acute schizophrenia clinical trial data.
Methods
Study data were pooled from six Phase II and III, 6-week, randomized, placebo-controlled trials that were conducted to test the efficacy, safety and tolerability of lurasidone for the acute treatment of schizophrenia and that were conducted either exclusively in the U.S. or that included study sites within the U.S. (2, 3, (13) (14) (15) . One additional 6-week lurasidone placebo-controlled trial (conducted entirely in Japan, Korea and Taiwan) has been recently completed but was not included in this analysis (16). Table 1 provides an outline of the number of subjects in each arm for each of the six clinical trials included in this report. More detailed descriptions of the individual studies can be found elsewhere in peerreviewed journals (2, 3), posters presented at scientific meetings (13, 14) , or publicly available regulatory documents (15). The subjects themselves were typical of those enrolled in registration studies for the acute treatment of schizophrenia (4, 5, 13, 15) . Mean age ranged from approximately 36-41 years, depending on the treatment arm, with 64-79% being men (13, 14) . Mean baseline PANSS total score ranged ITT=Intent-to-Treat; NA=not applicable; XR=extended release *Safety population consisted of all randomized subjects who received at least one dose of study medication. †Intent-to-Treat population consisted of all subjects who were randomized, received at least one dose of study medication, and had a baseline and at least one post-baseline Positive and Negative Syndrome Scale measure. ‡This was a failed study. Neither lurasidone nor the active control statistically separated from placebo on the primary psychopathological outcome measure. §This study was completed after the manufacturer submitted their New Drug Application to the FDA. The studies included in this analysis were all designed to compare lurasidone with placebo and, thus, powered as such. When an active control was used, it was for the purposes of assay sensitivity. Thus, all calculations for NNT or NNH are for antipsychotic vs. placebo. The NNT vs. placebo for the PANSS responder threshold outcomes and completer rates and NNH vs. placebo for all other outcomes were calthe proportion (n/N) of subjects for each treatment arm meeting the criterion of a ≥20%, 30%, 40% and 50% reduction from baseline to last observation carried forward (LOCF) endpoint on the Positive and Negative Syndrome Scale (PANSS) total score (reduction calculated by [PANSS total score at baseline-PANSS total score at LOCF endpoint]/[PANSS total score at baseline-30]). N, the denominator, is the Intent-toTreat population (all subjects who were randomized, received at least one dose of study medication, and had a baseline and at least one post-baseline PANSS assessment; excluded was the failed study where neither lurasidone nor the active control separated from placebo and, hence, that study was not informative about efficacy).
Phase
the proportion (n/N) of subjects for each treatment arm who completed the study and the proportion of subjects for each treatment arm who discontinued specifically due to an adverse event (AE) . N is the safety population (all randomized subjects who received at least one dose of study medication; all six studies were included).
the proportion (n/N) of subjects for each treatment arm who experienced weight gain of ≥7% from baseline at LOCF endpoint. N is the safety population.
the proportion (n/N) of subjects for each treatment arm who spontaneously reported AEs by event type. N is the safety population. AEs were obtained from the clinical trial reports. Selected were those AEs where the pooled incidence rate for all lurasidone doses was at least 5% (rounded upwards in case of incidence >4.5%): headache, akathisia, nausea, sedation, somnolence, insomnia, vomiting, dyspepsia, parkinsonism (or extrapyramidal disorder), anxiety, agitation and dizziness.
the proportion of subjects (n/N) with a fasting total cholesterol value ≥240 mg/dL, fasting low-density lipoprotein cholesterol ≥160 mg/dL, fasting triglyceride ≥200 mg/dL and fasting glucose ≥126 mg/dL at LOCF endpoint. N is the safety population and where a baseline and at least one post-baseline assessment for each metabolic variable were available.
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culated from the pooled proportions. NNT or NNH can be calculated by first computing the difference in proportions between the experimental intervention and the control intervention for the outcome of interest (risk difference), and then computing the reciprocal of the risk difference and rounding up to the next highest whole number (9). Calculating the 95% confidence interval (CI) for the NNT or NNH involves first calculating the 95% CI for the risk difference; the formula for this can be found elsewhere (9). When the 95% CI for the NNT or NNH estimate contains infinity, the NNT or NNH estimate is not statistically significant at the P threshold of <0.05 and under those circumstances, instead of providing the 95% CI, the notation "ns" for not significant is made. All calculations for NNT and NNH were done using the active medication as the experimental intervention and placebo as the control intervention, with the assumption that the study medication would be superior to placebo on efficacy outcomes but inferior to placebo on safety or tolerability outcomes. Thus, a negative NNT denotes an advantage for placebo over study medication regarding a potential benefit and a negative NNH denotes an advantage for study medication over placebo regarding a potential harm. Table 2 provides the responder rates and the NNT vs. placebo for the different treatment arms using pooled data for each dose of lurasidone, excluding data from a single failed study where neither lurasidone nor haloperidol statistically separated from placebo (15). Responder rates decreased as the threshold for response increased from 20 to 50%. All doses of lurasidone demonstrated a statistically significant NNT vs. placebo at all thresholds for response, with the exception of lurasidone 120 mg/d for the outcome of ≥50% reduction in PANSS total score. The most robust NNT values for lurasidone were observed for 160 mg/d; the data for this dose are limited to one study (13). Figure 1 graphically displays the NNT vs. placebo for response for the different doses of lurasidone.
Results
In order to determine the impact of the failed study on the overall pattern of results, these PANSS analyses were repeated by including the failed study in the pooling process. Results were similar and are presented in Table S1 in the supplementary appendix. Table 4 provides the rates and NNH for clinically relevant weight gain, as defined by an increase in body weight from baseline ≥7%. No statistically significant disadvantage from placebo on this outcome was observed for any dose of lurasidone or for haloperidol. However, NNH vs. placebo for clinically relevant weight gain at study endpoint was 4 (95% CI 3-5) for olanzapine and 9 (95% CI 6-22) for quetiapine extended-release, in contrast to a NNH for this outcome ranging from 43 (ns) to 150 (ns) for doses of lurasidone 40-160 mg/d. This is consistent with the outlier analysis for abnormal metabolic variables as presented in Table 5 , where the only statistically significant differences from placebo were observed for the outcome of triglycerides ≥200 mg/dL at LOCF endpoint demonstrating an advantage for lurasidone 160 mg/d vs. placebo with a NNH of -11 (95% CI -7 to -34) and a disadvantage of olanzapine vs. placebo with a NNH of 9 (95% CI 5-40). Table 6A outlines the incidence of the 12 most commonly encountered spontaneously reported AEs associated with lurasidone (all doses; incidence at least 5% after rounding). However, for many of these AEs, the difference from placebo was small. Only 5 AEs had consistently different rates when comparing most of the doses of lurasidone vs. placebo. These are noted in Table 6B listing the NNH values and are: akathisia, nausea, sedation, somnolence and parkinsonism. These are also graphically presented in Figure 2 . Lurasidone 160 mg/d appears better tolerated than lurasidone 40, 80 and 120 mg/d regarding akathisia, nausea, sedation and somnolence. As noted, the data for lurasidone 160 mg/d came from a single study. The design and conduct of that study was similar to the others with the exception that lurasidone was administered in the evening, in contrast to the five other studies where study medication was administered in the morning. The active controls demonstrated clinically relevant NNH values vs. placebo as would be expected from their individual clinical profiles: haloperidol was associated with low (i.e., more robust) NNH values for akathisia, parkinsonism and sedation, olanzapine with sedation, and quetiapine extended-release with dizziness. Figures 1 and 2 can be used to contrast trade-offs between efficacy and tolerability outcomes. Although in most instances the NNT would be lower than the NNH (and, hence, the benefit would be encountered more often than the harm), this may not always be the case as, for example, lurasidone 120 mg/d and the NNH vs. placebo for akathisia. LHH can be calculated to help quantify these trade-offs, as illustrated in Table 7 where NNT for response (defined by ≥30% decrease in PANSS from baseline; data excluding the failed study) is contrasted with NNH for akathisia, nausea, 
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NNT=number needed to treat; n.s.=not significant; PANSS=Positive and Negative Syndrome Scale NNH=number needed to harm; n.s.=not significant. *NNH for sedation for lurasidone 160 mg/d is -38 (n.s.). Shaded entries represent NNH values where the 95% CI does not include infinity and, hence, considered statistically significant. CI=confidence interval; NA=not applicable; NNH=number needed to harm; ns=not significant (the 95% CI contains "infinity"); XR=extended release. *A negative NNH denotes an advantage for study medication regarding the potential harm. A LHH of 5.0 for lurasidone 160 mg/d for response vs. parkinsonism can be interpreted that "lurasidone treatment at 160 mg/d is 5 times more likely to help the patient (≥30% decrease in PANSS) than harm the patient (parkinsonism). " For olanzapine 15 mg/d, NNT vs. placebo for ≥30% decrease in PANSS from baseline is 4 and NNH for weight increase ≥7% at study endpoint is 4, yielding a LHH of 1.0, which can be interpreted as "olanzapine treatment at 15 mg/d is equally likely to help the patient (≥30% decrease in PANSS) as harm the patient (weight gain ≥7%). " Note that when calculating and applying the LHH the benefit and the harm must be clinically relevant with regard to the individual being treated. Benefits and harms can also have different time courses and/or enduring consequences that also require careful consideration (11). Kraemer and Kupfer (17) propose that NNTs of 3 (rounded up from 2.3), 4 (rounded up from 3.6), and 9 (rounded up from 8.9) correspond to a Cohen's d of 0.8, 0.5, and 0.2, respectively, representing effect sizes that are "large, " "medium, " and "small. " In general, the therapeutic effects of lurasidone vs. placebo resulted in single digit NNT values, as did the active controls olanzapine 15 mg/d and quetiap-ine extended-release 600 mg/d. For lurasidone 160 mg/d the NNT was as robust as 3 (medium-large effect size) for a threshold of improvement of ≥20% on the PANSS, with the 95% CI overlapping that for olanzapine and quetiapine. Effect size differences from placebo generally became weaker as the threshold for response was increased from 20 to 50%. A caveat is that studies with high placebo response rates will yield NNT values that are less robust and will make cross-study comparisons difficult to interpret; this becomes relevant in this report when examining the NNT vs. placebo for the active controls.
Adverse Event
Discussion
Tolerability outcome differences for lurasidone vs. placebo resulted in NNH values that were in the double digits (with only one exception). This produced LHH values that were consistently favorable. Clinically, additional considerations include the time to onset of the adverse event versus time to onset of a therapeutic response, as well as the severity and duration of the adverse event. The adverse event in question may be easily manageable if it is non-serious and short-lived. The numerically lower incidence of akathisia with lurasidone 160 mg/d compared to 40, 80 or 120 mg/d will need to be further explored in additional studies, but may be reflective of the different time of administration of the medication (evening vs. morning dosing). With respect to metabolic outcomes, no adverse safety signal was evident for lurasidone across all doses in the examination of clinically relevant weight gain or laboratory abnormalities, in contrast to that observed with the active controls olanzapine and quetiapine.
In another published paper, NNH for the outcomes of weight gain ≥7% from baseline and AEs of somnolence, akathisia, or discontinuation due to an AE have been reported for the oral, first-line, second-generation antipsychotics vs. placebo, as calculated from their U.S. product labels (18). In that analysis, NNH for weight gain was the most favorable for lurasidone (NNH 63) compared with a NNH of 6 for olanzapine or quetiapine immediate-release and NNH values ranging from 12 to 35 for the other antipsychotics; NNH for somnolence was 9 for lurasidone, compared with 7 for olanzapine or quetiapine XR and 10 to 42 for the other antipsychotics; NNH for akathisia was 9 for lurasidone compared to 15 and higher for the other antipsychotics; NNH for discontinuation due to an AE was 30 for lurasidone, compared with 41 and higher for the other antipsychotics (18). When examining the data for the active controls in the included lurasidone studies, the NNH vs. placebo for discontinuation because of an AE was 12 for haloperidol, 17 for olanzapine and -28 for quetiapine XR (all ns). From product labeling (1), there are no AEs associated with discontinuation in subjects treated with lurasidone that were at least 2% and at least twice the placebo rate. For example, from the data available at the time of drug approval, akathisia resulted in discontinuation in 1.7% of patients treated with lurasidone vs. 0% for placebo (15). Of interest are the rates of discontinuation because of an AE in the study whose results were not available at the time of drug approval and where medication was administered in the evening (13): 3.3% for lurasidone 160 mg/d, 4.0% for lurasidone 80 mg/d, 3.4% for quetiapine XR 600 mg/d and 4.1% for placebo.
A major limitation of NNT and NNH is that these metrics are limited to dichotomous outcomes. Other effect size measures are necessary when describing continuous outcomes, such as mean changes in PANSS scores or mean changes in fasting plasma glucose levels (17, 19) .
A caveat regarding the crude metabolic outcomes presented here is that they do not take into account individual baseline risk. It is important to distinguish shifts from normal to abnormal values vs. from borderline to abnormal values. Moreover, high-density lipoprotein cholesterol was not examined. Although the blood for metabolic testing was to be obtained fasting, confirmation of this was not always available.
Data were obtained from carefully structured studies and, hence, the results may not be generalizable to patients outside the confines of a clinical trial. This is always a concern for results of registration trials because of the strict inclusion/exclusion criteria that these studies require. In addition, the studies were of a fixed-dose design; although this can reveal information about potential dose response for efficacy or tolerability outcomes, a flexible-dose methodology would better mirror clinical practice where the prescriber would adjust the dose based on the individual person's relief of symptoms and/or the emergence of adverse events.
Long-term efficacy, safety and tolerability, including maintenance of response are also important considerations in the selection of antipsychotics. Dichotomous outcomes from long-term trials, such as relapse and weight gain exceeding a predefined threshold, will be of interest in further appraising the clinical profile of lurasidone.
Conclusions
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